Signature Estate & Investment Advisors LLC Cuts Position in Pfizer Inc. (NYSE:PFE)

Signature Estate & Investment Advisors LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 27.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 7,154 shares of the biopharmaceutical company’s stock after selling 2,773 shares during the quarter. Signature Estate & Investment Advisors LLC’s holdings in Pfizer were worth $280,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp increased its holdings in shares of Pfizer by 0.5% in the 4th quarter. State Street Corp now owns 291,791,099 shares of the biopharmaceutical company’s stock valued at $11,432,375,000 after purchasing an additional 1,521,665 shares in the last quarter. Fisher Asset Management LLC increased its holdings in Pfizer by 2.6% during the 3rd quarter. Fisher Asset Management LLC now owns 45,291,398 shares of the biopharmaceutical company’s stock valued at $1,627,320,000 after acquiring an additional 1,158,147 shares in the last quarter. Sanders Capital LLC increased its holdings in Pfizer by 12.4% during the 4th quarter. Sanders Capital LLC now owns 26,496,116 shares of the biopharmaceutical company’s stock valued at $1,178,047,000 after acquiring an additional 2,913,496 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in Pfizer by 2.4% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 23,028,788 shares of the biopharmaceutical company’s stock valued at $902,268,000 after acquiring an additional 535,800 shares in the last quarter. Finally, Boston Partners increased its holdings in Pfizer by 1.3% during the 4th quarter. Boston Partners now owns 22,718,244 shares of the biopharmaceutical company’s stock valued at $890,093,000 after acquiring an additional 300,226 shares in the last quarter. Institutional investors and hedge funds own 70.16% of the company’s stock.

In other news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction on Thursday, January 30th. The shares were bought at an average cost of $37.15 per share, with a total value of $37,150.00. Following the purchase, the director now directly owns 4,000 shares of the company’s stock, valued at $148,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.09% of the stock is owned by company insiders.

Several equities analysts have weighed in on PFE shares. Cantor Fitzgerald restated a “buy” rating and set a $53.00 target price on shares of Pfizer in a report on Wednesday, January 29th. JPMorgan Chase & Co. restated a “neutral” rating and set a $37.00 target price on shares of Pfizer in a report on Tuesday, January 28th. Credit Suisse Group restated a “hold” rating and set a $41.30 target price on shares of Pfizer in a report on Wednesday, November 6th. Mizuho started coverage on shares of Pfizer in a report on Wednesday, February 5th. They set a “buy” rating and a $42.00 target price for the company. Finally, Royal Bank of Canada started coverage on shares of Pfizer in a report on Monday, January 6th. They set an “outperform” rating and a $46.00 target price for the company. Nine equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $41.72.

Shares of Pfizer stock traded down $0.37 during mid-day trading on Friday, hitting $36.56. 13,378,790 shares of the stock were exchanged, compared to its average volume of 23,319,768. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $44.56. The stock has a market capitalization of $209.25 billion, a price-to-earnings ratio of 12.74, a price-to-earnings-growth ratio of 3.09 and a beta of 0.67. The company has a 50-day simple moving average of $39.03 and a 200 day simple moving average of $37.57. The company has a current ratio of 0.90, a quick ratio of 0.68 and a debt-to-equity ratio of 0.55.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 28th. The biopharmaceutical company reported $0.55 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.57 by ($0.02). Pfizer had a return on equity of 27.23% and a net margin of 31.44%. The firm had revenue of $12.69 billion for the quarter, compared to analyst estimates of $12.73 billion. During the same period in the prior year, the business earned $0.64 earnings per share. Pfizer’s revenue for the quarter was down 9.2% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.76 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 31st will be paid a dividend of $0.38 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.36. This represents a $1.52 annualized dividend and a dividend yield of 4.16%. The ex-dividend date is Thursday, January 30th. Pfizer’s dividend payout ratio (DPR) is currently 51.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: Diversification in Investing

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.